P102 Safety evaluation from an ongoing randomized, double-blind, multiple-ascending dose phase Ib study of enpatoran versus placebo in patients with active systemic or cutaneous lupus erythematosus (SLE/CLE)

Ижил төстэй зүйлс

• P102 Safety evaluation from an ongoing randomized, double-blind, multiple-ascending dose phase Ib study of enpatoran versus placebo in patients with active systemic or cutaneous lupus erythematosus (SLE/CLE)
  -н: Torsten Witte, зэрэг
  Хэвлэсэн: (2024-03-01)
• Enpatoran in COVID‐19 pneumonia: Safety and efficacy results from a phase II randomized trial
  -н: John E. McKinnon, зэрэг
  Хэвлэсэн: (2023-12-01)
• Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll‐like receptors 7 and 8
  -н: Andreas Port, зэрэг
  Хэвлэсэн: (2021-10-01)
• Psoriatic microRNAs induce NK cell activation via an innate immune crosstalk abrogated by the Toll-like receptor 7/8 antagonist Enpatoran
  -н: Carolina Gaudenzi, зэрэг
  Хэвлэсэн: (2026-03-01)
• LP-183 Enpatoran: preclinical evidence supporting glucocorticoid dose reduction and phase II study design in patients with SLE and/or CLE (WILLOW)
  -н: Victoria P Werth, зэрэг
  Хэвлэсэн: (2023-07-01)